US Stock MarketDetailed Quotes
NBY NovaBay Pharmaceuticals
- 0.6810
- -0.0388-5.39%
Close Nov 22 16:00 ET
3.33MMarket Cap-10P/E (TTM)
0.7150High0.6806Low33.00KVolume0.7150Open0.7198Pre Close22.89KTurnover0.68%Turnover RatioLossP/E (Static)4.89MShares10.727552wk High3.12P/B3.32MFloat Cap0.361152wk Low--Dividend TTM4.88MShs Float130156.1979Historical High--Div YieldTTM4.78%Amplitude0.3610Historical Low0.6930Avg Price1Lot Size
NovaBay Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -1.61%2.44M | -32.09%2.4M | 12.48%2.63M | 2.24%14.73M | 74.91%6.37M | -35.15%2.48M | -3.50%3.53M | -28.54%2.34M | 41.16%14.4M | 14.81%3.64M |
| Operating revenue | -1.90%2.42M | -32.25%2.39M | 12.52%2.62M | 2.18%14.69M | 75.19%6.36M | -35.25%2.47M | -3.74%3.52M | -28.62%2.33M | 41.20%14.37M | 14.61%3.63M |
| Cost of revenue | 3.54%848K | -54.99%808K | 13.26%837K | 3.14%6.83M | 84.22%3.48M | -43.56%819K | -1.59%1.8M | -49.35%739K | 79.53%6.62M | 26.29%1.89M |
| Gross profit | -4.15%1.59M | -8.45%1.59M | 12.13%1.79M | 1.47%7.9M | 64.90%2.89M | -30.02%1.66M | -5.39%1.74M | -11.80%1.6M | 19.43%7.78M | 4.59%1.76M |
| Operating expense | 12.46%2.65M | -5.20%2.65M | 14.26%3.37M | -16.58%12.9M | 8.08%4.8M | -16.67%2.36M | -30.08%2.79M | -29.81%2.95M | 0.55%15.46M | -8.78%4.44M |
| Selling and administrative expenses | 12.48%2.65M | -4.77%2.64M | 14.00%3.35M | -16.07%12.83M | 8.98%4.77M | -15.59%2.36M | -29.92%2.77M | -29.58%2.94M | -0.30%15.29M | -9.99%4.38M |
| -Selling and marketing expense | -25.02%947K | -13.28%1.02M | -14.64%1.06M | -16.65%6.5M | 45.82%2.83M | -31.17%1.26M | -42.40%1.18M | -37.35%1.24M | -3.65%7.8M | -9.90%1.94M |
| -General and administrative expense | 55.81%1.7M | 1.51%1.62M | 34.84%2.29M | -15.48%6.33M | -20.29%1.95M | 14.33%1.09M | -16.60%1.59M | -22.60%1.7M | 3.44%7.49M | -10.06%2.44M |
| Research and development costs | 0.00%4K | -59.09%9K | 90.00%19K | -60.92%68K | -51.52%32K | -90.24%4K | -45.00%22K | -64.29%10K | 295.45%174K | 725.00%66K |
| Operating profit | -52.01%-1.06M | -0.19%-1.05M | -16.80%-1.57M | 34.86%-5M | 29.01%-1.91M | -52.74%-698K | 51.16%-1.05M | 43.53%-1.35M | 13.34%-7.68M | 15.81%-2.69M |
| Net non-operating interest income expense | 78.93%-138K | 40.12%-300K | -433K | -655K | -501K | 0 | ||||
| Non-operating interest expense | -78.93%138K | -40.12%300K | --433K | ---- | ---- | --655K | --501K | --0 | ---- | ---- |
| Other net income (expense) | -13K | -31.82%-232K | -1.09M | -58.37%-4.64M | 19.14%-4.46M | -5,766.67%-176K | -196.38%-2.93M | -281.72%-5.52M | ||
| Gain on sale of security | ---- | -163.67%-163K | --259K | -99.43%20K | -124.18%-236K | ---- | --256K | ---- | -23.64%3.52M | --976K |
| Special income (charges) | ---13K | --0 | ---865K | 58.01%-2.59M | 59.45%-2.59M | --0 | --0 | --0 | ---6.18M | ---6.4M |
| -Less：Restructuring and merger&acquisition | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---561K | ---342K |
| -Less:Impairment of capital assets | ---- | ---- | ---- | -61.51%2.59M | ---- | ---- | ---- | ---- | --6.74M | ---- |
| -Less:Other special charges | --13K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Gain on sale of business | --0 | --0 | ---865K | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Other non- operating income (expenses) | ---- | 84.03%-69K | ---480K | -647.83%-2.06M | -1,565.31%-1.63M | ---- | -14,300.00%-432K | ---- | 82.50%-276K | 93.79%-98K |
| Income before tax | 10.42%-1.21M | 8.28%-1.59M | -129.74%-3.09M | 9.13%-9.64M | 36.46%-5.21M | -894.85%-1.35M | 19.81%-1.73M | -1,111.71%-1.35M | -82.14%-10.61M | -5,093.67%-8.21M |
| Income tax | ||||||||||
| Net income | 31.02%-1.21M | 22.15%-1.59M | -84.82%-3.21M | 9.13%-9.64M | 49.94%-4.11M | -1,191.91%-1.76M | 5.52%-2.04M | -1,466.67%-1.74M | -82.14%-10.61M | -5,093.67%-8.21M |
| Net income continuous Operations | 10.42%-1.21M | 8.28%-1.59M | -129.74%-3.09M | 9.13%-9.64M | 36.46%-5.21M | -894.85%-1.35M | 19.81%-1.73M | -1,111.71%-1.35M | -82.14%-10.61M | -5,093.67%-8.21M |
| Net income discontinuous operations | --0 | --0 | 68.53%-124K | ---- | ---- | ---404K | ---308K | ---394K | ---- | ---- |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 31.02%-1.21M | 22.15%-1.59M | -84.82%-3.21M | 9.13%-9.64M | 49.94%-4.11M | -1,191.91%-1.76M | 5.52%-2.04M | -1,466.67%-1.74M | -82.14%-10.61M | -5,093.67%-8.21M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | 1.01M | 0 | 380K | 24.75%7.06M | 5.06M | 0 | 2M | 0 | 5.66M | 0 |
| Net income attributable to common stockholders | -26.18%-2.22M | 60.69%-1.59M | -106.67%-3.59M | -2.66%-16.7M | -11.74%-9.17M | 69.67%-1.76M | -87.10%-4.03M | -1,466.67%-1.74M | -147.98%-16.27M | -818.92%-8.21M |
| Basic earnings per share | 95.42%-0.6 | 96.92%-1.37 | 82.35%-5.25 | 60.79%-138.6 | 82.92%-28.5762 | 89.62%-13.11 | 11.23%-44.43 | -962.50%-29.75 | -92.02%-353.5 | -573.24%-167.3 |
| Diluted earnings per share | 95.42%-0.6 | 96.92%-1.37 | 82.35%-5.25 | 60.79%-138.6 | 82.92%-28.5762 | 89.62%-13.11 | 11.23%-44.43 | -962.50%-29.75 | -92.02%-353.5 | -573.24%-167.3 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data